FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149807823> ?p ?o ?g. }

• W2149807823 endingPage "694" @default.
• W2149807823 startingPage "689" @default.
• W2149807823 abstract "BackgroundThere is a clinical need to improve the efficacy of standard cetuximab + concurrent intensity-modulated radiation therapy (IMRT) for patients with locally and/or regionally advanced HNSCC. Taxanes have radiosensitizing activity against HNSCC, and nab-paclitaxel may offer therapeutic advantage in comparison with other taxanes.Patients and methodsThis was a single-institution phase I study with a modified 3 + 3 design. Four dose levels (DLs) of weekly nab-paclitaxel were explored (30, 45, 60, and 80 mg/m2), given with standard weekly cetuximab (450 mg/m2 loading dose followed by 250 mg/m2 weekly) and concurrent IMRT (total dose, 70 Gy).ResultsTwenty-five eligible patients (20 M, 5 F) enrolled, with median age 58 years (range, 46–84 years). Primary tumor sites were oropharynx, 19 (10 human papillomavirus [HPV] pos, 8 HPV neg, 1 not done); neck node with unknown primary, 2; larynx 2; and oral cavity and maxillary sinus, 1 each. Seven patients had received prior induction chemotherapy. Maximum tolerated dose (MTD) was exceeded at DL4 (nab-paclitaxel, 80 mg/m2) with three dose-limiting toxicities (DLTs) (grade 3 neuropathy, grade 3 dehydration, with grade 3 mucositis grade 3 anemia) among five assessable patients. There was only one DLT (grade 3 supraventricular tachycardia) among six patients at DL3 (nab-paclitaxel, 60 mg/m2), and this was deemed the MTD. Among 23 assessable patients, the most common ≥ g3 AEs were lymphopenia 100%, functional mucositis 65%, and pain in throat/oral cavity 52%. At a median follow-up of 33 months, 2-year failure-free survival (FFS) is 65% [95% confidence interval (CI) 42% to 81%] and 2-year overall survival (OS) is 91% (95% CI 69–97).ConclusionThe recommended phase II dose for nab-paclitaxel is 60 mg/m2 weekly when given standard weekly cetuximab and concurrent IMRT. This regimen merits further study as a nonplatinum alternative to IMRT + cetuximab alone.Clinicaltrials.gov IDNCT00736619." @default.
• W2149807823 created "2016-06-24" @default.
• W2149807823 creator A5005775817 @default.
• W2149807823 creator A5012610706 @default.
• W2149807823 creator A5024957945 @default.
• W2149807823 creator A5037147372 @default.
• W2149807823 creator A5055884560 @default.
• W2149807823 creator A5056163184 @default.
• W2149807823 creator A5058658514 @default.
• W2149807823 creator A5061365371 @default.
• W2149807823 creator A5065763505 @default.
• W2149807823 creator A5071357841 @default.
• W2149807823 creator A5072271778 @default.
• W2149807823 creator A5075751716 @default.
• W2149807823 creator A5077597527 @default.
• W2149807823 creator A5079540895 @default.
• W2149807823 creator A5085498397 @default.
• W2149807823 creator A5088827470 @default.
• W2149807823 date "2014-03-01" @default.
• W2149807823 modified "2023-10-16" @default.
• W2149807823 title "Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC)" @default.
• W2149807823 cites W1647414470 @default.
• W2149807823 cites W1868704956 @default.
• W2149807823 cites W1995429237 @default.
• W2149807823 cites W2004764525 @default.
• W2149807823 cites W2015167754 @default.
• W2149807823 cites W2016882655 @default.
• W2149807823 cites W2058984926 @default.
• W2149807823 cites W2061501822 @default.
• W2149807823 cites W2080435382 @default.
• W2149807823 cites W2080691119 @default.
• W2149807823 cites W2085935699 @default.
• W2149807823 cites W2109426463 @default.
• W2149807823 cites W2124117830 @default.
• W2149807823 cites W2127605299 @default.
• W2149807823 cites W2132513531 @default.
• W2149807823 cites W2132551046 @default.
• W2149807823 cites W2136693809 @default.
• W2149807823 cites W2137178561 @default.
• W2149807823 cites W2146488048 @default.
• W2149807823 cites W2151730005 @default.
• W2149807823 cites W2153017356 @default.
• W2149807823 cites W2154546143 @default.
• W2149807823 cites W2155384808 @default.
• W2149807823 cites W2164067249 @default.
• W2149807823 cites W2172288146 @default.
• W2149807823 cites W2241518838 @default.
• W2149807823 cites W2272017712 @default.
• W2149807823 cites W2035927009 @default.
• W2149807823 doi "https://doi.org/10.1093/annonc/mdt579" @default.
• W2149807823 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4433511" @default.
• W2149807823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24496920" @default.
• W2149807823 hasPublicationYear "2014" @default.
• W2149807823 type Work @default.
• W2149807823 sameAs 2149807823 @default.
• W2149807823 citedByCount "22" @default.
• W2149807823 countsByYear W21498078232015 @default.
• W2149807823 countsByYear W21498078232016 @default.
• W2149807823 countsByYear W21498078232017 @default.
• W2149807823 countsByYear W21498078232018 @default.
• W2149807823 countsByYear W21498078232019 @default.
• W2149807823 countsByYear W21498078232020 @default.
• W2149807823 countsByYear W21498078232021 @default.
• W2149807823 countsByYear W21498078232022 @default.
• W2149807823 countsByYear W21498078232023 @default.
• W2149807823 crossrefType "journal-article" @default.
• W2149807823 hasAuthorship W2149807823A5005775817 @default.
• W2149807823 hasAuthorship W2149807823A5012610706 @default.
• W2149807823 hasAuthorship W2149807823A5024957945 @default.
• W2149807823 hasAuthorship W2149807823A5037147372 @default.
• W2149807823 hasAuthorship W2149807823A5055884560 @default.
• W2149807823 hasAuthorship W2149807823A5056163184 @default.
• W2149807823 hasAuthorship W2149807823A5058658514 @default.
• W2149807823 hasAuthorship W2149807823A5061365371 @default.
• W2149807823 hasAuthorship W2149807823A5065763505 @default.
• W2149807823 hasAuthorship W2149807823A5071357841 @default.
• W2149807823 hasAuthorship W2149807823A5072271778 @default.
• W2149807823 hasAuthorship W2149807823A5075751716 @default.
• W2149807823 hasAuthorship W2149807823A5077597527 @default.
• W2149807823 hasAuthorship W2149807823A5079540895 @default.
• W2149807823 hasAuthorship W2149807823A5085498397 @default.
• W2149807823 hasAuthorship W2149807823A5088827470 @default.
• W2149807823 hasBestOaLocation W21498078231 @default.
• W2149807823 hasConcept C121608353 @default.
• W2149807823 hasConcept C126322002 @default.
• W2149807823 hasConcept C143998085 @default.
• W2149807823 hasConcept C2776530083 @default.
• W2149807823 hasConcept C2776694085 @default.
• W2149807823 hasConcept C2776833033 @default.
• W2149807823 hasConcept C2778496288 @default.
• W2149807823 hasConcept C2779998722 @default.
• W2149807823 hasConcept C31760486 @default.
• W2149807823 hasConcept C509974204 @default.
• W2149807823 hasConcept C526805850 @default.
• W2149807823 hasConcept C71924100 @default.
• W2149807823 hasConcept C90924648 @default.
• W2149807823 hasConceptScore W2149807823C121608353 @default.
• W2149807823 hasConceptScore W2149807823C126322002 @default.

• next